Nama's AI scorecard currently rates SI-BONE Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does SIBN report earnings?

SI-BONE's next scheduled report is on Feb 22, 2027. Analysts expect EPS of -$0.13.

What is the SIBN price target?

The median analyst price target from 9 analysts is $26.00, with a range of $23.00 – $32.00.

Is SIBN Shariah compliant?

Nama's AAOIFI-style screen reads SI-BONE as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

SI-BONE (SIBN)

Healthcare · Medical Devices · NASDAQ

SI-BONE (SIBN) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.09B and a free-cash-flow yield of -0.9%. Over the most recent reported fiscal year, revenue grew 20.2%. Nama's AI scorecard rates it Hold, 4.8 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 4.8/10

The sections balance. As of Nov 6, 2026.

Momentum

Rising · +25.7% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-17.9%

How far the last close sits under the highest price of the past five years.

Market cap	$1.09B
Trailing P/E	—
Price / book	5.9
Price / sales	5.1
FCF yield	-0.9%
Dividend yield	—
Gross margin	79.5%
Operating margin	-8.3%
Net margin	-6.8%
Revenue growth (YoY)	+20.2%
Revenue growth (3-yr annual)	+23.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.7
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

SIBN earnings

Next report: Feb 22, 2027 (Q4 2026, EPS estimate -$0.13). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	-$0.08	-$0.13	+38.5%	$55.70M
Q2 2026	Aug 3, 2026	-$0.09	-$0.15	+40.0%	$56.01M
Q1 2026	May 11, 2026	-$0.10	-$0.19	+47.4%	$52.59M
Q4 2025	Feb 23, 2026	-$0.04	-$0.13	+69.2%	$56.35M

SIBN analyst price target

Median target $26.00 from 9 analysts, ranging $23.00 – $32.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live SIBN data on Nama Insights →

SIBN FAQ

Is SIBN a buy?: Nama's AI scorecard currently rates SI-BONE Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SIBN report earnings?: SI-BONE's next scheduled report is on Feb 22, 2027. Analysts expect EPS of -$0.13.
What is the SIBN price target?: The median analyst price target from 9 analysts is $26.00, with a range of $23.00 – $32.00.
Is SIBN Shariah compliant?: Nama's AAOIFI-style screen reads SI-BONE as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.